The abstract is read at the publisher; the summary is JClub's.
Bits to Binders evaluated 12,000 generative AI-designed protein recognition domains for CAR T cells, identifying promising binder candidates for future cell therapies.
- Why it matters: Protein binder design needs rigorous, prospective benchmarking to determine how much emerging AI methods improve therapeutic discovery beyond retrospective claims.
- What they did: Kosonocky, Abel and colleagues ran the Bits to Binders competition by testing 12,000 designed proteins as recognition domains in engineered T cells.
- The result: The competition’s engineered-cell testing linked generative AI binder designs to promising candidates, supporting their use as leads for subsequent cell-therapy development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.